KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Tax Provisions (2019 - 2025)

Historic Tax Provisions for Alnylam Pharmaceuticals (ALNY) over the last 10 years, with Q3 2025 value amounting to -$12.1 million.

  • Alnylam Pharmaceuticals' Tax Provisions fell 51675.27% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.5 million, marking a year-over-year decrease of 77659.5%. This contributed to the annual value of -$99.2 million for FY2024, which is 157536.06% down from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Tax Provisions of -$12.1 million as of Q3 2025, which was down 51675.27% from $30.9 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Tax Provisions registered a high of $30.9 million during Q2 2025, and its lowest value of -$110.2 million during Q4 2024.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Tax Provisions value was $1.2 million (recorded in 2021), while the average stood at -$2.8 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Tax Provisions skyrocketed by 1309130.43% in 2023 and then tumbled by 6031584.7% in 2024.
  • Alnylam Pharmaceuticals' Tax Provisions (Quarter) stood at -$1.8 million in 2021, then surged by 125.62% to $472000.0 in 2022, then tumbled by 61.23% to $183000.0 in 2023, then tumbled by 60315.85% to -$110.2 million in 2024, then soared by 89.01% to -$12.1 million in 2025.
  • Its Tax Provisions stands at -$12.1 million for Q3 2025, versus $30.9 million for Q2 2025 and $15.9 million for Q1 2025.